GlassScriptPhysician profile
Robert S Mastman
NPI 1386683191
$3,493.57
in general payments reported to CMS, 2019-2025
22 companies · $878 in 2025
The $878 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $297 · 2021: $260 · 2022: $541 · 2023: $535 · 2024: $405 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797 · Entertainment: $21.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,796.71 |
| Entertainment | $21.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $503.75 | 2019-2025 | Cequa, Xelpros |
| Aerie Pharmaceuticals, INC. | $384.49 | 2019-2021 | |
| Oyster Point Pharma, INC. | $325.23 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $319.90 | 2019-2023 | |
| Abbvie INC. | $305.70 | 2023-2025 | |
| Alcon Vision LLC | $300.07 | 2022-2025 | Rocklatan, Tryptyr, Eysuvis |
| Notal Vision, INC. | $238.31 | 2022 | |
| Allergan, INC. | $173.71 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $156.95 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Rxsight INC | $148.12 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Kala Pharmaceuticals, INC. | $136.80 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $93.17 | 2019-2021 | |
| Amgen INC. | $79.60 | 2025 | Tepezza |
| Thea Pharma INC. | $66.10 | 2024-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $59.70 | 2024-2025 | Xdemvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $45.18 | 2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $36.21 | 2021 | |
| Biotissue Holdings INC. | $33.58 | 2019 | |
| Mallinckrodt Hospital Products INC. | $23.79 | 2025 | Acthar |
| Akorn, INC. | $22.75 | 2019 | |
| Optos, INC. | $21.69 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Astellas Pharma US INC | $18.77 | 2023 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mastman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.